MR引导SBRT推量治疗不适合近距离放疗的局部晚期或复发妇科癌症患者:可行性与早期临床经验
本研究回顾性分析10例不适合近距离放疗的局部晚期或复发妇科癌症患者,在盆腔放化疗后行MR引导SBRT推量,中位总剂量21.0 Gy分4次,中位随访9个月未见CTCAE≥II级毒性,早期结果报告该方案可行,需长期随访验证。
要点
- 10例不适合近距离放疗的局部晚期或复发妇科癌症患者接受MR引导SBRT推量,中位总剂量21.0 Gy分4次。
- 中位随访9个月,未观察到CTCAE≥II级毒性。
- 作者结论认为早期结果报告该方案可行,需长期随访验证。
核心结论
- 早期结果报告MR引导SBRT推量方案对不适合近距离放疗的局部晚期或复发妇科癌症患者可行。
- 遵循经典近距离放疗危及器官约束时,治疗耐受良好。
- 需长期随访验证结果。
研究设计与样本
- 回顾性分析10例局部晚期或复发妇科癌症患者。
- 患者因盆腔壁广泛浸润(10%)、其他邻近器官受累(30%)、两者兼有(50%)或无法麻醉(10%)而不适合近距离放疗。
- 采用在线自适应治疗计划以控制分次间解剖变化,评估治疗参数与毒性以判断MR引导SBRT推量的可行性。
主要发现
- MR引导SBRT推量中位总剂量21.0 Gy,分4次。
- 中位优化PTV(PTVopt)大小为43.5ccm,PTVopt中位累积剂量为73.6Gy10。
- 直肠D2ccm累积中位剂量63.7 Gy,膀胱72.2 Gy,乙状结肠65.8 Gy,肠道59.9 Gy(EQD23)。
- 中位总治疗时间/分次为77分钟,100%分次包含自适应工作流程,整个治疗中位持续时间50天。
- 中位随访9个月,未观察到CTCAE≥II级毒性。
局限性
- 回顾性分析。
- 需长期随访验证结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: Chemoradiotherapy (CRT) followed by a brachytherapy (BT) boost is the standard of care for patients with locally advanced or recurrent gynecological cancer (LARGC). However, not every patient is suitable for BT. Therefore, we investigated the feasibility of an MR-guided SBRT boost (MRg-SBRT boost) following CRT of the pelvis. MATERIAL AND METHODS: Ten patients with LARGC were analyzed retrospectively. The patients were not suitable for BT due to extensive infiltration of the pelvic wall (10%), other adjacent organs (30%), or both (50%), or ineligibility for anesthesia (10%). Online-adaptive treatment planning was performed to control for interfractional anatomical changes. Treatment parameters and toxicity were evaluated to assess the feasibility of MRg-SBRT boost. RESULTS: MRg-SBRT boost was delivered to a median total dose of 21.0 Gy in 4 fractions. The median optimized PTV (PTVopt) size was 43.5ccm. The median cumulative dose of 73.6Gy10 was delivered to PTVopt. The cumulative median D2ccm of the rectum was 63.7 Gy; bladder 72.2 Gy; sigmoid 65.8 Gy; bowel 59.9 Gy (EQD23). The median overall treatment time/fraction was 77 min, including the adaptive workflow in 100% of fractions. The median duration of the entire treatment was 50 days. After a median follow-up of 9 months, we observed no CTCAE ≥ °II toxicities. CONCLUSION: These early results report the feasibility of an MRg-SBRT boost approach in patients with LARGC, who were not candidates for BT. When classical BT-OAR constraints are followed, the therapy was well tolerated. Long-term follow-up is needed to validate the results.
引用
- Hadi I, Eze C, Schönecker S, et al. MR-guided SBRT boost for patients with locally advanced or recurrent gynecological cancers ineligible for brachytherapy: feasibility and early clinical experience. Radiat Oncol. 2022. PMID: 35033132. doi:10.1186/s13014-022-01981-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。